Havens Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Havens Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-24,993	Closed	-$861K	–	49
2020 Q3	$861K	Buy	+24,993	New	+$532K	0.8%	24

Havens Advisors's AIMT Position: Q4 2020 in Review

Havens Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 24,993 shares — an estimated $861K sold.

Havens Advisors first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $861K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Havens Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Havens Advisors sold 24,993 Aimmune Therapeutics shares in Q4 2020, an estimated $861K.
Havens Advisors first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Havens Advisors's Aimmune Therapeutics position peaked at $861K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Havens Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.